Original Data

Type 1 Diabetes Development Requires Both CD4+ and CD8+ T cells and Can Be Reversed by Non-Depleting Antibodies Targeting Both T Cell Populations

Jenny M. Phillips, Nicole M. Parish, Tim Raine, Chris Bland, Yvonne Sawyer, Hugo De La Peña, Anne Cooke

Manuscript submitted July 15, 2009; resubmitted July 27, 2009; accepted August 4, 2009.

Keywords: type 1 diabetes, T cell, CD4+, CD8+, NOD, NOD.scid, pancreas infiltration, CD8 alpha chain, dendritic cell, IgG2 antibody, aCD3 antibody

Abstract

Type 1 diabetes development in NOD mice appears to require both CD4⁺ and CD8⁺ T cells. However, there are some situations where it has been suggested that either CD4⁺ or CD8⁺ T cells are able to mediate diabetes in the absence of the other population. In the case of transgenic mice, this may reflect the numbers of antigen-specific T cells able to access the pancreas and recruit other cell types such as macrophages leading to a release of high concentrations of damaging cytokines. Previous studies examining the requirement for CD8⁺ T cells have used antibodies specific for CD8α. It is known that CD8α is expressed not only on αβ T cells, but also on other cell types, including a DC population that may be critical for presenting islet antigen in the pancreatic draining lymph nodes. Therefore, we have re-examined the need for both CD4⁺ and CD8⁺ T cell populations in diabetes development in NOD mice using an antibody to CD8β. Our studies indicate that by using highly purified populations of T cells and antibodies specific for CD8⁺ T cells, there is indeed a need for both cell types. In accordance with some other reports, we found that CD4⁺ T cells appeared to be able to access the pancreas more readily than CD8⁺ T cells. Despite the ability of CD4⁺ T cells to recruit CD11b class II positive cells, diabetes did not develop in the absence of CD8⁺ T cells. These studies support the observation that CD8⁺ T cells may be final effector cells. As both T cell populations are clearly implicated in diabetes development, we have used a combination of non-depleting antibodies to target both CD4-positive and CD8-positive cells and found that this antibody combination was able to reverse diabetes onset in NOD mice as effectively as anti-CD3 antibodies.

Fulltext: HTML , PDF (231KB)

This article has been cited by other articles:

	Pathogenic Mechanisms in Type 1 Diabetes: The Islet is Both Target and Driver of Disease Graham KL, Sutherland RM, Mannering SI, Zhao Y, Chee J, Krishnamurthy B, Thomas HE, Lew AM, Kay TW Rev Diabet Stud 2012. 9(4):148-168
	CNTF protects MIN6 cells against apoptosis induced by Alloxan and IL-1beta through downregulation of the AMPK pathway Santos GJ, Oliveira CA, Boschero AC, Rezende LF Cell Signal 2011. 23(10):1669-1676
	Autoimmunity and inflammation: murine models and translational studies Hall SW, Cooke A Mamm Genome 2011. 22(7-8):377-389
	B cell depletion in autoimmune diabetes: insights from murine models Chamberlain JL, Attridge K, Wang CJ, Ryan GA, Walker LS Expert Opin Ther Targets 2011. 15(6):703-714
	The role of natural killer T (NKT) cells in the pathogenesis of type 1 diabetes Gomez-Diaz RA, Aguilar MV, Meguro EN, Marquez RH, Magana EG, Martinez-García MC, Rodarte NW, Aguilar-Salinas CA, Canche-Pool E, Ortiz-Navarrete V Curr Diabetes Rev 2011. 7(4):278-283
	What causes type 1 diabetes? Lessons from animal models Buschard K APMIS Suppl 2011. 119(s132):1-19
	Immune cell crosstalk in type 1 diabetes Lehuen A, Diana J, Zaccone P, Cooke A Nat Rev Immunol 2010. 10(7):501-513
	Roles for TGF-beta and programmed cell death 1 ligand 1 in regulatory T cell expansion and diabetes suppression by zymosan in nonobese diabetic mice Burton OT, Zaccone P, Phillips JM, De La Pena H, Fehervari Z, Azuma M, Gibbs S, Stockinger B, Cooke A J Immunol 2010. 185(5):2754-2762
	Harnessing CD8+ regulatory T cells: therapy for type 1 diabetes? Zaccone P, Cooke A Immunity 2010. 32(4):504-506
	Breakthrough in diabetes therapy ... Just around the corner? Rudert WA, Trucco M Rev Diabet Stud 2009. 6(2):76-80